On November 6, 2026 Precision Biologics, Inc. CEO Philip M. Arlen, MD reported presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC. Recent tumor killing data showing specific non-toxic anti-tumor activity in human cancer expressing truncated core 2 O-glycans will be reported in "In vivo efficacy of the antibody-drug conjugate (ADC) PB-vcMMAE-5 in an ovarian cancer patient-derived xenograft (PDX) model expressing truncated core 2 O-glycans", at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2026, November 7th, 2026, Phoenix Convention Center, Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This highly sensitive and specific monoclonal antibody (mAb) PB-223 that internalizes into cancer cells expressing its target enables the opportunity for a high degree of anti-tumor response to our ADC with minimal toxicity in preclinical animal studies. The unique target is found on a broad variety of human solid tumors but not on healthy tissue, suggesting a strong rationale to move this drug into clinical development," said Dr. Arlen.
"We’re excited to further discuss PB-223 ADC with the scientific community, to share for the first time new compelling preclinical data showing ovarian cancer patient-derived xenograph human tumor models (PDX) treated with PB-223 ADC resulted in complete tumor eradication, with minimal toxicity observed in blood and healthy tissue," he went on to say.
Here are details of the presentation:
Title:
"In vivo efficacy of the antibody-drug conjugate (ADC) PB-vcMMAE-5 in an ovarian cancer patient-derived xenograft (PDX) model expressing truncated core 2 O-glycans"
Date/Time:
Saturday, November 7th, 12:30pm – 1:30pm – Day 2 –
Place:
SITC 2026, (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting),
Phoenix Convention Center – North Building, Lower Level – Exhibition Halls 4 – 6
Primary Category:
Immuno-Conjugates and Chimeric Molecules, Poster no. #888
Link to poster:
(Press release, Precision Biologics, NOV 6, 2026, View Source [SID1234674414])